Spyre Therapeutics, Inc.
SYREHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Spyre Therapeutics, Inc. focuses on Biotechnology services and products. Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The $8.59B market capitalization puts SYRE squarely in mid-cap range for its industry. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A).
Market Cap
$8.59B
Beta
3.02
P/E (TTM)
—
P/E (Fwd)
-31.63
EPS (TTM)
$-2.12
EPS (Fwd)
$-3.13
ROE
-31.1%
ROA
-22.7%
Cash
$741.5M
Total Debt
$0
Free CF
-$75.5M
52W Change
512.2%
Annual Financials
Cash vs Debt
Spyre Therapeutics, Inc. reports $741.5M in cash and $0 in total debt. Free cash flow is running at -$75.5M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -31.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $2.3M (2022) to $0 (2025), a 100% decline worth watching.
With a beta above 1.5, SYRE tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Spyre Therapeutics, Inc. and its sector.